After signing up, you'll start to receive regular news updates from us.
Anthill Technologies Announces Agreement with Zafgen
Complete the form below to unlock access to ALL audio articles.
Anthill Technologies, Inc. has announced that it has entered into an agreement with Zafgen, Inc. to apply its high-speed chemistry technologies and capabilities to Zafgen's obesity program.
Zafgen, Inc. is a Boston-based biopharmaceutical company which develops obesity therapy based on the vascular targeting of adipose tissue.
Under the agreement, Anthill will use its ACOS™ high-speed synthesis and on-demand purification capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs.
"We are very pleased to have the opportunity to assist Zafgen in its efforts to find novel and effective therapies to combat obesity," said Dr. Joseph C. Hogan Jr., CEO of Anthill Technologies. "We fully expect that our high-speed chemistry expertise and unique capabilities will help Zafgen to accelerate its obesity therapy discovery program."
